Director Cam Gallagher purchases 164,000 shares at $1.97–$1.98 for $323.7K, raising stake 9.3% amid -42.3% revenue decline and $-17.5M annual loss.
Director Cam Gallagher executed two separate purchases totaling 164,000 shares for $323,693.40 on 2025-12-29 at prices of $1.98 and $1.97, increasing his holdings from 1,760,430 to 1,924,430 shares (+9.3%). The timing occurs within a deteriorating operational backdrop: the company reported annual revenue decline of -42.3% year-over-year, a net loss of $-17,454,000.00 for the full fiscal year, and quarterly revenue of $3,079,000.00. The current stock price of $2.01 sits -19.6% below the 52-week high of $2.50, placing the transaction within 1.5% of current market levels. Investors should note the magnitude of the director's open-market commitment—164.0K shares represents meaningful capital allocation—alongside the concurrent negative fundamentals and margin erosion, which warrant assessment of what visibility or strategic rationale this purchase reflects given Opus Genetics' unprofitable status and steep revenue contraction.